We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Radiotherapy Breakthrough May Lead to Highly Accurate Cancer Treatment

Two technicians fitting a patient's face mask for protection during radiotherapy.
Credit: National Cancer Institute
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 3 minutes

An important breakthrough in the development of a new and highly accurate radiotherapy treatment for cancer has been achieved.


The new treatment, called FLASH RT, is as effective as current techniques but could also prevent unnecessary damage to healthy tissue and considerably shorten the time that patients spend in hospital.


Scientists at the National Physical Laboratory (NPL), including IPEM Fellow Russell Thomas, Science Area Leader of Medical Radiation Science, used a pioneering measurement technology to measure and standardise the absorbed dose for a potentially revolutionary form of proton beam radiotherapy known as FLASH.


The breakthrough led to the first in-human clinical trial of FLASH RT in November 2020, involving 10 patients at the Cincinnati Children’s Hospital’s Proton Therapy Centre in Ohio, USA. The findings of the NPL team’s research were published in Nature in February (‘Absolute dosimetry for FLASH proton pencil beam scanning radiotherapy’).

Ultra-high dose rate radiation

The FLASH RT technique uses short pulses of ultra-high dose rate (UHDR) radiation to treat cancer. Currently, any form of radiotherapy results in some undesirable and unavoidable deposition of radiation to healthy tissues around the targeted tumour. Studies have suggested that treatment using UHDR radiation exposures could significantly spare healthy tissue whilst being at least as effective as treatments at conventional dose rates in controlling the tumour. This has been named ‘the FLASH effect’. 

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

Using a NPL designed and built device called a proton calorimeter, the NPL team conducted research to calibrate the UHDR radiation dose needed for treatments at a much reduced uncertainty of +/- 0.9 percent. The calorimeter quantified the amount of energy absorbed from the radiotherapy by first measuring the temperature rise caused by a typical patient treatment: and then converting it into ‘Grays’ (Gy), the unit of measurement for ionizing radiation used in cancer treatment. For a typical patient fraction of 2 Gy, this would equate to a temperature rise of less than 0.003o C.

Standardised dose measurements

Mr Thomas said: ‘In 2003, an exploratory project collaborating with Dr Andrzej Kacperek and his team at The National Centre for Eye Proton Therapy at the Clatterbridge Cancer Centre, examined how NPL might support improvements in dosimetry for Proton Radiotherapy. That initial discussion grew into a 20-year long collaboration that has resulted in us developing not only a world-leading portable primary standard calorimeter for proton therapy but a device that we can use, directly in the clinic, to help standardise dose measurements from promising treatment techniques like FLASH and other ion therapies such as Carbon and Helium beams as they become more widely adopted by the clinical community.’


Ana Lourenço, Senior Research Scientist at NPL’s Medical Radiation Science group, added: ‘This work has increased our understanding of the characteristics of this type of beams and will be invaluable in the development of future protocols to enable safe and accurate implementation in the clinic of this significant treatment technique. The work done during this trial has provided the hospital with the confidence to commence clinical implementation of this important new technology.’


Dr Anthony Mascia, Director of Medical Physics, Cincinnati Children’s Hospital, Proton Therapy Center, University of Cincinnati, Department of Radiation Oncology, said: ‘In support of the world’s first in-human clinical trial (FAST-01) for proton ultra-high dose rate (UHDR) FLASH radiotherapy (FRT), the collaboration between Cincinnati Children’s Hospital and the National Physical Laboratory was instrumental in validating the absolute dose methodology, using an advanced, NPL-designed calorimeter well suited for true absolute dose measurements, particularly in a high dose rate environment. 


‘The work from this collaboration is truly first-of-its-kind and of highly scientific and clinical value, as evidenced by multiple publications, presentations and invited talks at national and international conferences. We, in Cincinnati, regard the scientists from the NPL as part of our large, extended team that helped successfully launch FAST-01.’

New dosimetry recommendations

The NPL is actively involved in producing new dosimetry recommendations for FLASH RT, which will be critical in harmonizing worldwide the dosimetry of UHDR beams and the underpinning of the FLASH mechanism.


Radiotherapy is used around the world as a treatment in up to 50 percent of all cancer cases. It is by far the most cost-effective method of cancer treatment when compared to surgery and chemotherapy. Accurate dosimetry is essential to avoid errors which might cause incorrect quantification of dose delivered to the patient and flawed interpretation of the clinical outcomes related to the FLASH effect. It could also reduce considerably the amount of time that cancer patients spend in hospital, freeing hospital staff and equipment to treat more patients and reducing both post-treatment complications and costs.


Reference: Lourenço A, Subiel A, Lee N, et al. Absolute dosimetry for FLASH proton pencil beam scanning radiotherapy. Sci Rep. 2023;13(1):2054. doi: 10.1038/s41598-023-28192-0



This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.